WAIT FOR SUGGESTIONS BY CATEGORY OR CONTINUE TYPING IN YOUR KEYWORDS
ENTER ONE OR MULTIPLE KEYWORDS & PRESS THE SEARCH BUTTON
Search
Favorites
Favorites
AdvancedMinimize
Clear
Pre-clinical studies and evaluation of treatment need of glatiramer acetate depot
Author(s):
N. Bleich-Kimelman
,
N. Bleich-Kimelman
Affiliations: Mapi-Pharma, Ness Ziona
S. Rubnov
,
S. Rubnov
Affiliations: Mapi-Pharma, Ness Ziona
U. Danon
,
U. Danon
Affiliations: Mapi-Pharma, Ness Ziona
E. Marom
,
E. Marom
Affiliations: Mapi-Pharma, Ness Ziona
A. Miller
A. Miller
Affiliations: Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel; Multiple Sclerosis & Brain Research Center, Carmel Medical Center, Haifa, Israel
Background: Glatiramer Acetate (GA) is the active pharmaceutical ingredient in Copaxone®, prescribed for treatment of relapsing remitting multiple sclerosis (RRMS). GA Depot is a long-acting formulation of GA intended for intramuscular (IM) injection once every 28 days. It is expected that GA Depot will significantly increase compliance of GA users and therefore will provide a therapeutic benefit.
Aims:
(1) to compare GA Depot activity to that of Copaxone®.
(2) to assess the unmet need for such formulation among current Copaxone® users.
Methods: GA Depot was evaluated in vitro for GA release profile. In vivo, GA Depot effect on clinical manifestations of EAE was compared to that of Copaxone®, using three EAE studies in C57BL/6 mice in which single IM dose of GA Depot was compared repeated daily subcutaneously doses of Copaxone®. Additionally, we conducted a Helsinki/IRB approved questioner study among RRMS patients that are treated with Copaxone® for at least 12 months in order to assess the clinical need for GA Depot.
Results: In vitro, GA Depot was found to release GA for 28 days in a constant rate. In vivo, EAE studies demonstrated that GA Depot effect on disease burden and symptoms is at least comparable to that of Copaxone®. In the questioner study, over 70% of subjects expressed:
(a) increased satisfaction if frequency of injections would be reduced from once daily to once monthly, and
(b) willingness to switch to IM GA Depot although it may cause increased injection site adverse events.
Conclusions: Experimental in vitro and in vivo data suggests that GA Depot has a potential beneficial effect in RRMS. Moreover, there is a clear unmet need for such treatment among Copaxone® treated RRMS patients. An open-labelled phase IIa clinical study is being conducted in Israel to test the safety, tolerability and efficacy of GA Depot.
Background: Glatiramer Acetate (GA) is the active pharmaceutical ingredient in Copaxone®, prescribed for treatment of relapsing remitting multiple sclerosis (RRMS). GA Depot is a long-acting formulation of GA intended for intramuscular (IM) injection once every 28 days. It is expected that GA Depot will significantly increase compliance of GA users and therefore will provide a therapeutic benefit.
Aims:
(1) to compare GA Depot activity to that of Copaxone®.
(2) to assess the unmet need for such formulation among current Copaxone® users.
Methods: GA Depot was evaluated in vitro for GA release profile. In vivo, GA Depot effect on clinical manifestations of EAE was compared to that of Copaxone®, using three EAE studies in C57BL/6 mice in which single IM dose of GA Depot was compared repeated daily subcutaneously doses of Copaxone®. Additionally, we conducted a Helsinki/IRB approved questioner study among RRMS patients that are treated with Copaxone® for at least 12 months in order to assess the clinical need for GA Depot.
Results: In vitro, GA Depot was found to release GA for 28 days in a constant rate. In vivo, EAE studies demonstrated that GA Depot effect on disease burden and symptoms is at least comparable to that of Copaxone®. In the questioner study, over 70% of subjects expressed:
(a) increased satisfaction if frequency of injections would be reduced from once daily to once monthly, and
(b) willingness to switch to IM GA Depot although it may cause increased injection site adverse events.
Conclusions: Experimental in vitro and in vivo data suggests that GA Depot has a potential beneficial effect in RRMS. Moreover, there is a clear unmet need for such treatment among Copaxone® treated RRMS patients. An open-labelled phase IIa clinical study is being conducted in Israel to test the safety, tolerability and efficacy of GA Depot.
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS). USER TERMS AND CONDITIONS | PRIVACY POLICY
Cookie Settings Accept Terms & all Cookies
Anonymous User Privacy Preferences
Strictly Necessary Cookies (Always Active)
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.
Google Analytics and Google Tag Manager embedded tracking functionalities are used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG's features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.